Kymera Therapeutics (KYMR) Q2 2024 earnings summary

Executive summary

• Significant progress in building a global biotech company focused on first-in-class degrader medicines targeting validated pathways for large, underserved diseases, with programs in immunology-inflammation and oncology, including IRAK4, STAT3, MDM2, STAT6, and TYK2.

• Pipeline advancements highlighted at major medical congresses and in peer-reviewed publications, with robust preclinical and clinical data across immunology and oncology programs.

• Sanofi to expand KT-474 (IRAK4) Phase 2 trials in HS and AD after positive interim safety and efficacy review, aiming to accelerate pivotal trial readiness.

• KT-621 (STAT6 degrader) to enter Phase 1 in H2 2024 after IND-enabling studies showed no safety findings; KT-294 (TYK2) to start Phase 1 in 2025.

• KT-253 (MDM2) and KT-333 (STAT3) oncology programs showed major responses in early trials, with Phase 1a dose escalation studies to complete enrollment in H2 2024.

Financial highlights

• Q2 2024 collaboration revenue was $25.7 million, all from Sanofi, up from $16.5 million in Q2 2023; six-month revenue was $35.9 million.

• R&D expenses were $59.2 million, with $7.3 million in non-cash stock-based compensation; G&A expenses were $17.4 million, with $7.1 million in non-cash stock-based compensation.

• Net loss for Q2 2024 was $42.1 million, compared to $38.8 million in Q2 2023.

• Cash, cash equivalents, and marketable securities totaled $702.4 million as of June 30, 2024, providing runway into H1 2027.

• Impairment charge of $4.9 million related to facility exit in 2024.

Outlook and guidance

• Cash runway supports execution of multiple data readouts, including oncology proof-of-concept in 2024 and key clinical milestones for STAT6 and TYK2 in 2025.

• KT-474 Phase 2 results expected beyond prior guidance of H1 2025 due to trial expansion.

• KT-621 (STAT6) Phase 1 to start in H2 2024; KT-294 (TYK2) Phase 1 to initiate in H1 2025.

• KT-253 and KT-333 Phase 1a enrollment to complete in H2 2024, with data readouts and next steps to be shared.

• Expects to require additional funding for late-stage development and commercialization.